(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 8 April 2004 (08.04.2004)

PCT

(10) International Publication Number WO 2004/029204 A2

(51) International Patent Classification7:

C12N

(74) Common Representative: MERCK & CO., INC.; 126

(21) International Application Number:

PCT/US2003/030161

(22) International Filing Date:

23 September 2003 (23.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/414,144

27 September 2002 (27.09.2002) US

- (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KOPKA, Ihor, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). LI, Bing [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). HAGMANN, William, K. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

- East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PYRIMIDINES

$$R^3$$
 N
 N
 R^1
 N

(57) Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



E COLIN BURNOU DE ROUTE COM COM COM CONTROL DE REPORT DE LOS ROUTE DE LOS ROUTES DE LO COMPANIO DE LO COMPANIO

(43) International Publication Date 8 April 2004 (08.04.2004)

PCT

(10) International Publication Number WO 2004/029204 A3

- (51) International Patent Classification⁷: C07D 239/28, 239/34, 239/36, 239/47, 239/48, 239/52, 239/58, A61K 31/505, 31/506, A61P 25/18, 25/28
- (21) International Application Number:

PCT/US2003/030161

(22) International Filing Date:

23 September 2003 (23.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/414,144

27 September 2002 (27.09.2002) US

- (71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): KOPKA, Ihor, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). LI, Bing [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). HAGMANN, William, K. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 17 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PYRIMIDINES

(57) Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.





Internal application No.

PCT/USO3/30161

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C07D 239/28, 239/34, 239/36, 239/47, 239/48, 239/52, 239/58; A61K 31/505, 31/506; A61P 25/18, 25/28 US CL : 544/ 309, 310, 315, 316, 319, 320, 326; 514/ 256, 269, 275 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: 544/ 309, 310, 315, 316, 319, 320, 326; 514/ 256, 269, 275			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ON LINE, EAST			
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.
Y	US 5,684,011 A (FITZJOHN et al) 04 November 1997 (04.11.1997), see entire document especially formula I on column 1 and Table I for compounds made shown on coulmn 8 through 12.		
Y	US 2002/0004600 A1 (MEYER et al) 10 January 2002 (10.01.2002), see entire document.		1-9
	·		
Furthe	r documents are listed in the continuation of Box C.	See patent family annex.	
Special categories of cited documents: "T" later document published after the international filing date of priority date and not in conflict with the application but cited understand the principle or theory underlying the invention." "A" document defining the general state of the art which is not considered to		the application but cited to	
be of particular relevance "B" carlier application or patent published on or after the international filing		*X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
to establ	ment which may throw doubts on priority claim(s) or which is cited "Y" tablish the publication date of another citation or other special reason specified) document of particular relevance; the claimed invention cannot be comsidered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		e claimed invention cannot be tep when the document is ch documents, such
"O" document referring to an oral disclosure, use, exhibition or other means "&" document member of the same patent family			
"P" document published prior to the international filing date but later than the			
Date of the actual completion of the international search Date of mailing of the international search Page of mailing of the international search Page of mailing of the international search			rch report
08 February 2004 (08.02.2004) Name and mailing address of the ISA/US A		Authorized officer	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Venkataraman Balasyoramining	
P.0	D. Box 1450 exandria, Virginia 22313-1450	Telephone No. (708)308-1235	//

Facsimile No. (703)305-3230
Form PCT/ISA/210 (second sheet) (July 1998)